AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2636644 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted protein intake (Control)
Number of subjects: 57
Study 2636644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD + EAA)
Number of subjects: 57
Study 342628 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent A/New Jersey/76 influenza virus vaccines (two-dose regimens)
Number of subjects: 264
Study 342628 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-virus and whole-virus vaccines
Number of subjects: 264
Study 342628 — intervention group
Group type: EXPERIMENTAL
Intervention: Two whole-virus vaccines
Number of subjects: 264
Study 30590811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA (AHI 5 to 14.9 events/hour)
Number of subjects: 744
Study 30590811 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSA (AHI 15 to 29.9 events/hour)
Number of subjects: 744
Study 30590811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA (overall)
Number of subjects: 744
Study 30590811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA in young and middle-aged adults
Number of subjects: 744
Study 30590811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate OSA in adults older than 60 years
Number of subjects: 744
Study 27844212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel (Treatment, n=35)
Number of subjects: 78
Study 27844212 — intervention group
Group type: COMPARATOR
Intervention: Control (n=31)
Number of subjects: 78
Study 25413898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 33
Study 25413898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24064159 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw support device used during dental scaling sessions
Number of subjects: 31
Study 24064159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device used) during dental scaling sessions
Number of subjects: 31
Study 21522097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 60
Study 21522097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral clonidine)
Number of subjects: 60
Study 20137491 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic variceal ligation plus octride (EVL group)
Number of subjects: 101
Study 20137491 — intervention group
Group type: COMPARATOR
Intervention: Octride alone (octride treatment group)
Number of subjects: 101
Study 16885180 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (10 mg/kg/day) for 14 days
Number of subjects: 33
Study 16885180 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily tobramycin (divided into three equal doses every 8 hours)
Number of subjects: 33
Study 14713803 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tolterodine ER once daily for 12 weeks
Number of subjects: 986
Study 14713803 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 986
Study 11216078 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0
Study 11216078 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 0
Study 9041666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccines
Number of subjects: 0
Study 9041666 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine
Number of subjects: 0
Study 9041666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines with individually purified components
Number of subjects: 0
Study 9041666 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell and component acellular vaccines
Number of subjects: 0
Study 9041666 — intervention group
Group type: EXPERIMENTAL
Intervention: Component acellular vaccines
Number of subjects: 0
Study 9041666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine recipients
Number of subjects: 0
Study 9041666 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 0
Study 8193869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management of GER
Number of subjects: 0
Study 8193869 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic methods
Number of subjects: 0
Study 8193869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal methods
Number of subjects: 0
Study 3253217 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg administered at 21h00
Number of subjects: 12
Study 3253217 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 09h00
Number of subjects: 12
Study 3253217 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 21h00
Number of subjects: 12
Study 3253217 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg administered at 09h00
Number of subjects: 12
Study 31690004 — intervention group
Group type: EXPERIMENTAL
Intervention: BBPAS (Brain Breaks Physical Activity Solutions)
Number of subjects: 322
Study 26840038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fasting blood glucose (<70 mg/dL)
Number of subjects: 18610
Study 26840038 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (100-125 mg/dL)
Number of subjects: 18610
Study 26840038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (≥126 mg/dL, use of antidiabetic medication and/or self-report)
Number of subjects: 18610
Study 25548316 — intervention group
Group type: EXPERIMENTAL
Intervention: Early support
Number of subjects: 297
Study 25548316 — intervention group
Group type: EXPERIMENTAL
Intervention: Late support
Number of subjects: 297
Study 25548316 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 297
Study 24257266 — intervention group
Group type: EXPERIMENTAL
Intervention: POWERS (physical activity only)
Number of subjects: 102
Study 24257266 — intervention group
Group type: EXPERIMENTAL
Intervention: POWERS(plus) (physical activity plus nutrition)
Number of subjects: 102
Study 24257266 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 21715542 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4)+I
Number of subjects: 1024
Study 21715542 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4)
Number of subjects: 1024
Study 21715542 — intervention group
Group type: EXPERIMENTAL
Intervention: I
Number of subjects: 1024
Study 21715542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1024
Study 19151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study 19151017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16304699 — intervention group
Group type: EXPERIMENTAL
Intervention: True exposure to RF field (1 W/kg SAR) for 30 min via a 900 MHz GSM mobile phone.
Number of subjects: 40
Study 16304699 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control condition).
Number of subjects: 40
Study 15172710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 50 mg
Number of subjects: 35
Study 15172710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10780756 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-MDI (fenoterol hydrobromide 50 microg and ipratropium bromide 20 microg)
Number of subjects: 2027
Study 10780756 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI (Berodual/Bronchodual)
Number of subjects: 2027
Study 10780756 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-MDI
Number of subjects: 2027
Study 10780756 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI
Number of subjects: 2027
Study 9060793 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg once per day) plus placebo; n = 14
Number of subjects: 46
Study 9060793 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (10 mg two times per day) plus placebo; n = 18
Number of subjects: 46
Study 9060793 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once per day) plus Nisoldipine (10 mg two times per day); n = 14
Number of subjects: 46
Study 8342506 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IA antiarrhythmic therapy
Number of subjects: 15
Study 3485054 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMBA (1.0 g)
Number of subjects: 74
Study 3485054 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 74
Study 29678799 — intervention group
Group type: EXPERIMENTAL
Intervention: WebQuit - 5-week users
Number of subjects: 2637
Study 29678799 — intervention group
Group type: EXPERIMENTAL
Intervention: WebQuit - 52-week users
Number of subjects: 2637
Study 29678799 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokefree - 5-week users
Number of subjects: 2637
Study 29678799 — intervention group
Group type: COMPARATOR
Intervention: Smokefree - 4-week users
Number of subjects: 2637
Study 27135464 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and Attention Adaptation Training (MAAT)
Number of subjects: 47
Study 27135464 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 47
Study 24534013 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 20
Study 24534013 — intervention group
Group type: COMPARATOR
Intervention: Saline control injection
Number of subjects: 20
Study 23402088 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Diltiazem gel (2%)
Number of subjects: 61
Study 23402088 — intervention group
Group type: COMPARATOR
Intervention: Topical Glyceril trinitrate ointment (0.2%)
Number of subjects: 61
Study 20303606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy biphasic external cardioversion at 20 or 30 J
Number of subjects: 0
Study 20303606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy biphasic external cardioversion
Number of subjects: 0
Study 18697207 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a at 270 microg/week plus ribavirin at 1600 mg/day
Number of subjects: 0
Study 18697207 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a at 270 microg/week plus ribavirin at 1200 mg/day
Number of subjects: 0
Study 18697207 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a at 180 microg/week plus ribavirin at 1600 mg/day
Number of subjects: 0
Study 18697207 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a at 180 microg/week plus ribavirin at 1200 mg/day
Number of subjects: 0
Study 15558604 — intervention group
Group type: EXPERIMENTAL
Intervention: bLES
Number of subjects: 60
Study 15558604 — intervention group
Group type: COMPARATOR
Intervention: Survanta
Number of subjects: 60
Study 12608685 — intervention group
Group type: EXPERIMENTAL
Intervention: STARS for Families program (intervention)
Number of subjects: 650
Study 10547245 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg OspA vaccine
Number of subjects: 250
Study 10547245 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg OspA vaccine
Number of subjects: 250
Study 10547245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of OspA vaccine
Number of subjects: 250
Study 9081395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 4 mg twice daily as maintenance
Number of subjects: 94
Study 9081395 — intervention group
Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 94
Study 1807972 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 3
Study 1807972 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 3
Study 1807972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 6338992 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 200
Study 6338992 — intervention group
Group type: COMPARATOR
Intervention: Control (no stockings)
Number of subjects: 200
Study 30908263 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact ultrasound tactile display
Number of subjects: 0
Study 30293053 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Based Learning (PBL)
Number of subjects: 108
Study 30293053 — intervention group
Group type: COMPARATOR
Intervention: PBL + Active Learning Model for Critical Thinking (ALMCT)
Number of subjects: 108
Study 26912506 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (i.v. infusion 1-5 µg/kg/h)
Number of subjects: 75
Study 26912506 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (loading dose 0.3-0.4 µg/kg followed by i.v. infusion 0.2-1 µg/kg/h)
Number of subjects: 75
Study 26912506 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 75
Study 26912506 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 75
Study 24390828 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 paravertebral block (PVB)
Number of subjects: 53
Study 24390828 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block (LPB)
Number of subjects: 53
Study 22465256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly, group-based weight management intervention with individualized calorie intake goal, second counseling session, and weekly group meetings until birth.
Number of subjects: 160
Study 22465256 — intervention group
Group type: COMPARATOR
Intervention: Single dietary advice control condition.
Number of subjects: 160
Study 22465256 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly, group-based weight management intervention.
Number of subjects: 160
Study 20667691 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training program for 6 months (Group 1)
Number of subjects: 11
Study 20667691 — intervention group
Group type: COMPARATOR
Intervention: No home-based training (Group 2)
Number of subjects: 11
Study 17355792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental stent during radiotherapy
Number of subjects: 43
Study 15616247 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening approach using fasting capillary glucose combined with age and BMI
Number of subjects: 30383
Study 15616247 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening approach using fasting capillary glucose
Number of subjects: 30383
Study 15616247 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMI as risk factors
Number of subjects: 30383
Study 15616247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary glucose
Number of subjects: 30383
Study 12780478 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire-12 (GHQ-12)
Number of subjects: 336
Study 10559513 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (86 mg daily for two menstrual cycles)
Number of subjects: 14
Study 10559513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for two menstrual cycles)
Number of subjects: 14
Study 10559513 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones and Placebo (cross-over effect)
Number of subjects: 14
Study 8698011 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 188
Study 8698011 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 188
Study 8698011 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 188
Study 8698011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 188
Study 8698011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 188
Study 8698011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment comparison
Number of subjects: 188
Study 1757607 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 84
Study 1757607 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment
Number of subjects: 84
Study 7129299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiopental
Number of subjects: 31
Study 7129299 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg methohexital
Number of subjects: 31
Study 7129299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 31879076 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Nursing Nutritional Intervention (ONNI)
Number of subjects: 152
Study 31879076 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 152
Study 30640585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) group
Number of subjects: 42
Study 30640585 — intervention group
Group type: COMPARATOR
Intervention: Lower back (LB) group
Number of subjects: 42
Study 28705573 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (oral administration for up to 12 weeks)
Number of subjects: 24
Study 26010861 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 29
Study 26010861 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 29
Study 26010861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 23314316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 305
Study 23314316 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol (n = 102)
Number of subjects: 305
Study 23314316 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐tocopherol (n = 102)
Number of subjects: 305
Study 20869883 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 50
Study 20869883 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 50
Study 19017314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (mean cumulative dose 35.4+/‐21.6 mg/m(2))
Number of subjects: 20
Study 19017314 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study 16500469 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal (FS)
Number of subjects: 45
Study 16500469 — intervention group
Group type: COMPARATOR
Intervention: Control (saline-soaked neuropatties)
Number of subjects: 45
Study 14716340 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (group B, n=7)
Number of subjects: 13
Study 14716340 — intervention group
Group type: COMPARATOR
Intervention: No therapy (group A, n=6)
Number of subjects: 13
Study 14716340 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy in patients relapsing directly into CRel (n=4)
Number of subjects: 13
Study 11129360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group
Number of subjects: 184
Study 11129360 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group
Number of subjects: 184
Study 11129360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 9293831 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions to maintain hemoglobin level of 10 g/dL
Number of subjects: 99
Study 9293831 — intervention group
Group type: COMPARATOR
Intervention: Transfusions to maintain hemoglobin level of 9 g/dL
Number of subjects: 99
Study 8112806 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and fat-rich diet
Number of subjects: 0
Study 8112806 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein coadministration
Number of subjects: 0
Study 8112806 — intervention group
Group type: COMPARATOR
Intervention: Fasting subjects
Number of subjects: 0
Study 3528460 — intervention group
Group type: EXPERIMENTAL
Intervention: Micromechanical retainers
Number of subjects: 0
Study 3528460 — intervention group
Group type: COMPARATOR
Intervention: Macromechanical retainers
Number of subjects: 0
Study 31495655 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCom cognitive rehabilitation software (ten 45‐min sessions in five weeks)
Number of subjects: 50
Study 31495655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 30646107 — intervention group
Group type: EXPERIMENTAL
Intervention: Greening intervention
Number of subjects: 0
Study 27673378 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal incision, multifidus-sparing MED
Number of subjects: 73
Study 27673378 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiskectomy
Number of subjects: 73
Study 27673378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 24321374 — intervention group
Group type: EXPERIMENTAL
Intervention: Drisapersen 3mg/kg
Number of subjects: 0
Study 24321374 — intervention group
Group type: EXPERIMENTAL
Intervention: Drisapersen 6mg/kg
Number of subjects: 0
Study 24321374 — intervention group
Group type: EXPERIMENTAL
Intervention: Drisapersen 9mg/kg
Number of subjects: 0
Study 22860301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal branch of the radial artery (DRA)
Number of subjects: 76
Study 22860301 — intervention group
Group type: COMPARATOR
Intervention: Radial artery (RA)
Number of subjects: 76
Study 20456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw unsalted peanuts (56 g daily for 4 weeks)
Number of subjects: 118
Study 20456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted unsalted peanuts (56 g daily for 4 weeks)
Number of subjects: 118
Study 20456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted salted peanuts (56 g daily for 4 weeks)
Number of subjects: 118
Study 20456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey roasted peanuts (56 g daily for 4 weeks)
Number of subjects: 118
Study 20456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut butter (56 g daily for 4 weeks)
Number of subjects: 118
Study 20456815 — intervention group
Group type: COMPARATOR
Intervention: Individuals with elevated fasting plasma lipids
Number of subjects: 118
Study 19138915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (1.5 mg.kg(‐1) bolus followed by 2 mg.kg(‐1).hr(‐1) continuous infusion)
Number of subjects: 50
Study 19138915 — intervention group
Group type: COMPARATOR
Intervention: Control group (fentanyl 3 microg.kg(‐1))
Number of subjects: 50
Study 19138915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 50
Study 19138915 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 17238334 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support system for implementing clinical guidelines
Number of subjects: 0
Study 17238334 — intervention group
Group type: EXPERIMENTAL
Intervention: Care with system support of the guideline
Number of subjects: 0